published meta-analysis   sensitivity analysis   studies

chloroquine and derivatives in COVID 19 all comers - Summary of results

OutcomeTE95% CInkI2ROBPub. bias deathsdetailed resultsNOR-Solidarity (hydroxychloroquine), 2021 3.10 [0.29; 33.20] 3.10[0.29; 33.20]NOR-Solidarity (hydroxychloroquine), 202110%112NAnot evaluable deaths (time to event analysis only)detailed resultsNOR-Solidarity (hydroxychloroquine), 2021 3.10 [0.29; 33.20] 3.10[0.29; 33.20]NOR-Solidarity (hydroxychloroquine), 202110%112NAnot evaluable0.55.01.0relative treatment effectwww.metaEvidence.org2024-11-04 22:40 +01:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 94 - treatments: 508,656,657,832 - roots T: 290